Paris (France), March 17, 2025 – PEP-Therapy, a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology, announced that the U.S. Food and Drug ...

Paris (France), April 25, 2024 – PEP-Therapy, a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology, and Institut Curie, France’s leading cancer ...

French biotech Pep-Therapy SAS is in the midst of raising a €20 million (US$21.62 million) round and, at the same time, prospecting for potential partners after winning FDA orphan drug designation for ...

PARIS--(BUSINESS WIRE)--PEP-Therapy, a biotechnology company developing targeted therapies for cancer treatments, has raised €1.3 million in initial funding. This sum, invested by the Quadrivium 1 ...

PEP-010 has received orphan drug designation for pancreatic cancer, emphasizing the need for novel treatments in this high-mortality disease. The peptide disrupts Caspase-9 and PP2A interaction, ...